Neuronetics, Inc. has announced a significant policy update from Optum/United Healthcare/United Behavioral Health, which now allows psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer Transcranial Magnetic Stimulation (TMS) therapy. Previously restricted to psychiatrists, this change enhances access to NeuroStar Advanced Therapy for the 34.8 million individuals covered by Optum/UHC/UBH in 26 states and Washington, D.C., thereby addressing a critical gap in mental health care delivery.

The implications of this policy shift are profound, particularly in light of the statistics surrounding major depressive disorder (MDD), which affects 21 million adults in the U.S. alone. Many patients experience inadequate relief from traditional antidepressants, making non-invasive treatments like NeuroStar TMS vital. The therapy has demonstrated impressive outcomes, with a reported 83% response rate and 62% remission rate among patients, according to the NeuroStar Outcomes Database. By empowering PMHNPs to deliver this therapy, the update not only broadens the treatment landscape but also aims to improve patient outcomes in underserved communities, where access to mental health care is often limited.

This policy change signifies a paradigm shift in mental health treatment accessibility and provider roles, potentially accelerating the integration of TMS therapy into standard care protocols. As PMHNPs step into this expanded role, it may lead to a more rapid adoption of innovative therapies like NeuroStar TMS, ultimately shortening drug development timelines and enhancing the quality of life for patients who have not responded to conventional treatments. The recognition of PMHNPs as qualified providers for TMS therapy underscores the evolving landscape of mental health care and the necessity for collaborative approaches in addressing mental health disorders.

Source: globenewswire.com